Evercore ISI Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $14.00

Jasper Therapeutics (NASDAQ:JSPR) had its price target lowered by Evercore ISI from $20.00 to $14.00 in a report published on Monday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other research analysts have also issued reports about the company. BMO Capital Markets reaffirmed a “market perform” rating on shares of Jasper Therapeutics in a research report on Tuesday, July 8th. UBS Group lowered their target price on Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, August 15th. HC Wainwright lowered their target price on Jasper Therapeutics from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 7th. JMP Securities lowered their target price on Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a research report on Monday. Finally, William Blair reaffirmed a “market perform” rating on shares of Jasper Therapeutics in a research report on Monday, July 7th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Jasper Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.63.

Jasper Therapeutics Stock Performance

Shares of JSPR opened at $2.33 on Monday. Jasper Therapeutics has a 52 week low of $2.27 and a 52 week high of $26.05. The stock has a market capitalization of $37.86 million, a price-to-earnings ratio of -0.39 and a beta of 2.77. The stock has a fifty day moving average of $2.82 and a 200-day moving average of $4.16.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.54). As a group, equities analysts forecast that Jasper Therapeutics will post -4.47 EPS for the current year.

Insiders Place Their Bets

In other Jasper Therapeutics news, CEO Ron Martell acquired 41,000 shares of the stock in a transaction dated Monday, September 22nd. The stock was purchased at an average cost of $2.43 per share, with a total value of $99,630.00. Following the transaction, the chief executive officer owned 74,118 shares in the company, valued at approximately $180,106.74. The trade was a 123.80% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Svetlana Lucas bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was purchased at an average cost of $2.43 per share, with a total value of $48,600.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at $48,600. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders bought 143,000 shares of company stock valued at $347,490. Insiders own 4.60% of the company’s stock.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in Jasper Therapeutics by 13.9% in the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock valued at $579,000 after buying an additional 3,310 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Jasper Therapeutics by 11.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after buying an additional 23,453 shares in the last quarter. Nuveen LLC bought a new stake in Jasper Therapeutics in the 1st quarter valued at about $440,000. Jefferies Financial Group Inc. bought a new stake in Jasper Therapeutics in the 4th quarter valued at about $668,000. Finally, Kingdon Capital Management L.L.C. increased its position in Jasper Therapeutics by 9.6% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 490,000 shares of the company’s stock valued at $2,107,000 after buying an additional 43,000 shares in the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.